Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)

被引：2

作者：

Salehzadeh, Farhad ^{[1
]}

Mohammadikebar, Yusef ^{[2
]}

Enteshary, Afsaneh ^{[2
]}

Ghanbarpour, Omid ^{[1
]}

Mirzarahimi, Mehrdad ^{[1
]}

机构：

[1] Ardabil Univ Med Sci ARUMS, Bouali Childrens Hosp, Dept Pediat, 105 Shahrak Azadi,Azerbaijan St, Ardebil 56157, Iran

[2] Ardabil Univ Med Sci ARUMS, Emam Khomeini Hosp, Dept Internal Med, Ardebil, Iran

来源：

BIOLOGICS-TARGETS & THERAPY | 2019年 / 13卷

关键词：

pyoderma gangrenosum; infliximab; childhood;

D O I：

10.2147/BTT.S203753

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much information available about infliximab use for biologic and childhood pyoderma gangrenosum, eventually we decided to use infliximab in this patient. Infliximab showed a dramatic response and resulted in full recovery during 2 years' follow-up.

引用

页码：97 / 99

页数：3

共 9 条

[1]

Benaffene N, 2003, ANN DERMATOL VENER, V130, P53

[2] Infantile Crohn disease presenting with diarrhea and pyoderma gangrenosum [J].